HK Stock MarketDetailed Quotes

01099 SINOPHARM

Watchlist
  • 20.400
  • +0.500+2.51%
Not Open Nov 7 16:08 CST
63.66BMarket Cap6.97P/E (TTM)

SINOPHARM Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Turnover
-0.78%442.42B
-2.07%294.73B
1.20%147.27B
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
Operating income
-0.78%442.42B
-2.07%294.73B
1.20%147.27B
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
Cost of sales
----
1.76%-272.78B
----
-8.59%-548.06B
----
-15.79%-277.68B
----
-5.81%-504.71B
----
-4.94%-239.81B
Operating expenses
0.34%-409.34B
1.76%-272.78B
-1.57%-136.69B
-8.59%-548.06B
-10.31%-410.72B
-15.79%-277.68B
-14.45%-134.58B
-5.81%-504.71B
-6.74%-372.34B
-4.94%-239.81B
Gross profit
-5.99%33.09B
-5.70%21.94B
-3.34%10.58B
2.27%48.51B
3.38%35.2B
7.45%23.27B
9.30%10.94B
7.68%47.43B
4.85%34.05B
5.20%21.66B
Selling expenses
-1.11%-12.79B
-0.54%-8.48B
-1.75%-4.21B
-4.50%-17.47B
-6.12%-12.65B
-8.44%-8.43B
-8.87%-4.13B
-8.30%-16.72B
-2.18%-11.92B
-2.26%-7.78B
Administrative expenses
2.84%-5.33B
1.33%-3.92B
-0.84%-1.75B
-6.04%-8.68B
-5.90%-5.48B
-8.43%-3.97B
-7.15%-1.74B
-5.44%-8.18B
-5.70%-5.18B
-6.33%-3.66B
Research and development expenses
24.99%-195.61M
----
25.87%-71.13M
----
-23.96%-260.77M
----
-55.73%-95.96M
----
-66.90%-210.37M
----
Profit from asset sales
-96.73%10.53M
----
-85.73%3.33M
-6.80%-2.07B
1,278.98%322.01M
----
545.49%23.3M
-71.22%-1.94B
-52.87%23.35M
----
Revaluation surplus
3,176.15%3.16M
----
135.67%20.9K
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
-Changes in the fair value of other assets
3,176.15%3.16M
----
135.67%20.9K
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
Impairment and provision
-9.74%-1.78B
-1.98%-1.32B
-14.48%-901.55M
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
-Other impairment is provision
-9.74%-1.78B
-1.98%-1.32B
-14.48%-901.55M
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
Special items of operating profit
-29.40%405.75M
-768.52%-12.17M
-27.35%213.15M
-13.92%582.01M
42.78%574.7M
101.04%1.82M
77.82%293.38M
14.76%676.16M
-33.62%402.52M
-205.35%-175.83M
Operating profit
-18.03%12.36B
-14.19%8.22B
-16.01%3.52B
-1.92%20.21B
1.56%15.07B
5.79%9.58B
9.36%4.19B
4.53%20.6B
2.03%14.84B
3.25%9.06B
Financing income
----
11.17%389.45M
----
36.96%743.37M
----
9.77%350.3M
----
-2.83%542.77M
----
1.80%319.13M
Financing cost
25.05%-1.52B
17.24%-1.46B
23.68%-427.49M
14.98%-3.17B
10.00%-2.03B
7.11%-1.77B
18.79%-560.15M
5.77%-3.73B
3.26%-2.25B
-0.25%-1.9B
Share of profits of associates
----
9.05%623.03M
----
4.46%1.11B
----
16.39%571.3M
----
-0.47%1.06B
----
8.04%490.85M
Share of profit from joint venture company
----
-43.27%1.69M
----
-244.88%-4.22M
----
46.72%2.98M
----
318.99%2.91M
----
239.87%2.03M
Special items of earning before tax
93.64%-1.24M
-237.28%-176M
635.15%27.71M
660.80%625.97M
-2,740.26%-19.47M
236.55%128.2M
-14.76%3.77M
121.89%82.28M
-96.94%737.47K
-49.38%38.09M
Earning before tax
-16.82%10.84B
-14.32%7.6B
-14.15%3.12B
5.11%19.51B
3.47%13.03B
10.77%8.87B
15.49%3.64B
9.18%18.56B
2.85%12.59B
3.72%8B
Tax
17.35%-2.45B
13.97%-1.7B
12.44%-724.85M
-6.73%-4.5B
-6.55%-2.96B
-11.14%-1.97B
-14.72%-827.84M
-7.11%-4.22B
-1.95%-2.78B
-5.13%-1.78B
After-tax profit from continuing operations
-16.67%8.39B
-14.42%5.9B
-14.65%2.4B
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
Earning after tax
-16.67%8.39B
-14.42%5.9B
-14.65%2.4B
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
Minority profit
-21.67%3.11B
-21.28%2.2B
-19.80%978.14M
2.34%5.96B
0.39%3.97B
10.02%2.79B
21.91%1.22B
9.68%5.82B
3.66%3.96B
3.65%2.53B
Adjustment items of profit attributable to shareholders
----
----
----
----
----
----
----
----
---0.01
----
Profit attributable to shareholders
-13.41%5.28B
-9.76%3.7B
-10.70%1.42B
6.19%9.05B
4.09%6.1B
11.12%4.1B
11.38%1.59B
9.89%8.53B
2.73%5.86B
3.10%3.69B
Basic earnings per share
-13.78%1.69
-9.85%1.19
-9.80%0.46
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
Diluted earnings per share
-13.78%1.69
-9.85%1.19
-9.80%0.46
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
Auditor
--
--
--
PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)
--
--
--
Ernst & Young Huaming (Special General Partnership), Ernst & Young
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Turnover -0.78%442.42B-2.07%294.73B1.20%147.27B8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B
Operating income -0.78%442.42B-2.07%294.73B1.20%147.27B8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B
Cost of sales ----1.76%-272.78B-----8.59%-548.06B-----15.79%-277.68B-----5.81%-504.71B-----4.94%-239.81B
Operating expenses 0.34%-409.34B1.76%-272.78B-1.57%-136.69B-8.59%-548.06B-10.31%-410.72B-15.79%-277.68B-14.45%-134.58B-5.81%-504.71B-6.74%-372.34B-4.94%-239.81B
Gross profit -5.99%33.09B-5.70%21.94B-3.34%10.58B2.27%48.51B3.38%35.2B7.45%23.27B9.30%10.94B7.68%47.43B4.85%34.05B5.20%21.66B
Selling expenses -1.11%-12.79B-0.54%-8.48B-1.75%-4.21B-4.50%-17.47B-6.12%-12.65B-8.44%-8.43B-8.87%-4.13B-8.30%-16.72B-2.18%-11.92B-2.26%-7.78B
Administrative expenses 2.84%-5.33B1.33%-3.92B-0.84%-1.75B-6.04%-8.68B-5.90%-5.48B-8.43%-3.97B-7.15%-1.74B-5.44%-8.18B-5.70%-5.18B-6.33%-3.66B
Research and development expenses 24.99%-195.61M----25.87%-71.13M-----23.96%-260.77M-----55.73%-95.96M-----66.90%-210.37M----
Profit from asset sales -96.73%10.53M-----85.73%3.33M-6.80%-2.07B1,278.98%322.01M----545.49%23.3M-71.22%-1.94B-52.87%23.35M----
Revaluation surplus 3,176.15%3.16M----135.67%20.9K-----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----
-Changes in the fair value of other assets 3,176.15%3.16M----135.67%20.9K-----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----
Impairment and provision -9.74%-1.78B-1.98%-1.32B-14.48%-901.55M-0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M
-Other impairment is provision -9.74%-1.78B-1.98%-1.32B-14.48%-901.55M-0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M
Special items of operating profit -29.40%405.75M-768.52%-12.17M-27.35%213.15M-13.92%582.01M42.78%574.7M101.04%1.82M77.82%293.38M14.76%676.16M-33.62%402.52M-205.35%-175.83M
Operating profit -18.03%12.36B-14.19%8.22B-16.01%3.52B-1.92%20.21B1.56%15.07B5.79%9.58B9.36%4.19B4.53%20.6B2.03%14.84B3.25%9.06B
Financing income ----11.17%389.45M----36.96%743.37M----9.77%350.3M-----2.83%542.77M----1.80%319.13M
Financing cost 25.05%-1.52B17.24%-1.46B23.68%-427.49M14.98%-3.17B10.00%-2.03B7.11%-1.77B18.79%-560.15M5.77%-3.73B3.26%-2.25B-0.25%-1.9B
Share of profits of associates ----9.05%623.03M----4.46%1.11B----16.39%571.3M-----0.47%1.06B----8.04%490.85M
Share of profit from joint venture company -----43.27%1.69M-----244.88%-4.22M----46.72%2.98M----318.99%2.91M----239.87%2.03M
Special items of earning before tax 93.64%-1.24M-237.28%-176M635.15%27.71M660.80%625.97M-2,740.26%-19.47M236.55%128.2M-14.76%3.77M121.89%82.28M-96.94%737.47K-49.38%38.09M
Earning before tax -16.82%10.84B-14.32%7.6B-14.15%3.12B5.11%19.51B3.47%13.03B10.77%8.87B15.49%3.64B9.18%18.56B2.85%12.59B3.72%8B
Tax 17.35%-2.45B13.97%-1.7B12.44%-724.85M-6.73%-4.5B-6.55%-2.96B-11.14%-1.97B-14.72%-827.84M-7.11%-4.22B-1.95%-2.78B-5.13%-1.78B
After-tax profit from continuing operations -16.67%8.39B-14.42%5.9B-14.65%2.4B4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B
Earning after tax -16.67%8.39B-14.42%5.9B-14.65%2.4B4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B
Minority profit -21.67%3.11B-21.28%2.2B-19.80%978.14M2.34%5.96B0.39%3.97B10.02%2.79B21.91%1.22B9.68%5.82B3.66%3.96B3.65%2.53B
Adjustment items of profit attributable to shareholders -----------------------------------0.01----
Profit attributable to shareholders -13.41%5.28B-9.76%3.7B-10.70%1.42B6.19%9.05B4.09%6.1B11.12%4.1B11.38%1.59B9.89%8.53B2.73%5.86B3.10%3.69B
Basic earnings per share -13.78%1.69-9.85%1.19-9.80%0.466.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.18
Diluted earnings per share -13.78%1.69-9.85%1.19-9.80%0.466.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.18
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions ------Unqualified Opinion------Unqualified Opinion----
Auditor ------PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)------Ernst & Young Huaming (Special General Partnership), Ernst & Young----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data